Skip to main content

We use cookies to understand how you use our site and to improve your experience.

This includes personalizing content and advertising.

By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.

You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.

In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

OK Cancel

Back to top

BridgeBio Pharma to Present Additional Positive PROPEL 3 Data and Multiple Achondroplasia and ADH1 Studies at ICCBH 2026

BridgeBio Pharma announces upcoming presentations on infigratinib and achondroplasia research at the ICCBH 2026 in Montreal.

Quiver AI Summary

BridgeBio Pharma, Inc. announced that new positive data from its global Phase 3 study, PROPEL 3, on oral infigratinib for children with achondroplasia will be presented at the International Congress of Children’s Bone Health (ICCBH) in Montreal from June 27-30, 2026. The presentation will be made by Dr. Ravi Savarirayan on June 28. Additionally, BridgeBio will share findings on health-related quality of life in children with achondroplasia and present multiple posters on early intervention, observational study results, and educational resources for families affected by achondroplasia. The company will also present findings on autosomal dominant hypocalcemia type 1 from its monitoring study, CLARIFY. BridgeBio focuses on developing treatments for genetic conditions, aiming to connect scientific advancements with meaningful therapies for underserved populations.

Potential Positives

  • Presentation of additional positive data from the PROPEL 3 study at a prominent international congress enhances BridgeBio's credibility and visibility in the biopharmaceutical space, particularly in the area of achieving meaningful advancements for children with achondroplasia.
  • Sharing findings related to quality of life and early intervention research further positions BridgeBio as a leader in addressing the needs and challenges of children with genetic conditions, potentially increasing interest from healthcare professionals and investors.
  • Engagement in knowledge dissemination through oral presentations and posters highlights BridgeBio's commitment to education and support for patients and families affected by achondroplasia and related skeletal dysplasias, which could foster community trust and loyalty.

Potential Negatives

  • While the press release highlights positive data from the PROPEL 3 study, it does not provide specifics on the efficacy or safety of oral infigratinib, which could leave stakeholders questioning the robustness of the data presented.
  • The mention of multiple presentations at an upcoming conference may indicate that the company is attempting to generate positive attention in lieu of securing concrete outcomes or approvals, which could be perceived as a strategy to maintain investor interest amidst uncertainties.

FAQ

What is the PROPEL 3 study focused on?

The PROPEL 3 study evaluates oral infigratinib in children with achondroplasia.

When will BridgeBio present at ICCBH 2026?

BridgeBio will present data at ICCBH from June 27-30, 2026, in Montreal, Canada.

Who is the presenter for the late-breaking oral presentation?

Ravi Savarirayan, M.D., Ph.D., will present the late-breaking oral session on June 28.

What educational resources will be shared at the conference?

BridgeBio will highlight MyAchonJourney and various observational studies related to achondroplasia.

What conditions does BridgeBio Pharma focus on?

BridgeBio focuses on developing medicines for genetic conditions, including achondroplasia and autosomal dominant hypocalcemia.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.


EARLY ACCESS
Receive BBIO Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

$BBIO Insider Trading Activity

BBIO Insider Trades

$BBIO insiders have traded $BBIO stock on the open market 81 times in the past 6 months. Of those trades, 0 have been purchases and 81 have been sales.

Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:

  • NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 66 sales selling 454,156 shares for an estimated $32,490,210.
  • JENNIFER E. COOK has made 0 purchases and 2 sales selling 90,240 shares for an estimated $6,012,157.
  • ANDREA ELLIS sold 64,921 shares for an estimated $4,211,301
  • RANDAL W. SCOTT has made 0 purchases and 7 sales selling 20,000 shares for an estimated $1,426,012.
  • THOMAS TRIMARCHI (President and CFO) has made 0 purchases and 2 sales selling 13,600 shares for an estimated $1,016,147.
  • HANNAH VALANTINE sold 8,671 shares for an estimated $624,312
  • MARICEL APULI (Chief Accounting Officer) has made 0 purchases and 2 sales selling 2,510 shares for an estimated $181,058.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$BBIO Congressional Stock Trading

Members of Congress have traded $BBIO stock 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $BBIO stock by members of Congress over the last 6 months:

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$BBIO Hedge Fund Activity

We have seen 259 institutional investors add shares of $BBIO stock to their portfolio, and 220 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$BBIO Analyst Ratings

Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • William Blair issued a "Outperform" rating on 03/10/2026
  • Barclays issued a "Overweight" rating on 01/28/2026
  • Truist Securities issued a "Buy" rating on 01/08/2026
  • Morgan Stanley issued a "Overweight" rating on 01/06/2026

To track analyst ratings and price targets for $BBIO, check out Quiver Quantitative's $BBIO forecast page.

$BBIO Price Targets

Multiple analysts have issued price targets for $BBIO recently. We have seen 12 analysts offer price targets for $BBIO in the last 6 months, with a median target of $98.0.

Here are some recent targets:

  • Salim Syed from Mizuho set a target price of $96.0 on 06/16/2026
  • Whitney Ijem from Canaccord Genuity set a target price of $104.0 on 06/03/2026
  • Raghuram Selvaraju from HC Wainwright & Co. set a target price of $110.0 on 05/28/2026
  • Sean Laaman from Morgan Stanley set a target price of $98.0 on 05/28/2026
  • Eric Joseph from Citigroup set a target price of $82.0 on 05/19/2026
  • Cory Kasimov from Evercore ISI Group set a target price of $130.0 on 05/08/2026
  • Danielle Brill from Truist Securities set a target price of $102.0 on 04/29/2026

Full Release

PALO ALTO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional positive data from PROPEL 3, the global Phase 3 pivotal study of oral infigratinib in children living with achondroplasia, will be shared in a late breaking oral presentation at the International Congress of Children’s Bone Health (ICCBH) 2026 taking place in Montreal, Canada on June 27-30, 2026.

BridgeBio will also share an oral presentation and four posters at the meeting highlighting quality of life, early intervention research, observational study findings, and educational resources through MyAchonJourney for individuals with achondroplasia and related skeletal dysplasias. Additionally, the Company will share an autosomal dominant hypocalcemia type 1 (ADH1) poster on findings from CLARIFY, its disease monitoring study of autosomal dominant hypocalcemia (ADH) type 1 and type 2.

Late-Breaking Oral Presentation:
A Randomized Controlled Trial of Oral Infigratinib in Children with Achondroplasia
Presenter: Ravi Savarirayan, M.D., Ph.D. of Murdoch Children’s Research Institute, Melbourne, AU, and Global Lead Investigator for PROPEL 3
Date & Time: Sunday, June 28 at 3:45 pm EDT

Oral Presentation:
Health-Related Quality of Life in Children with Achondroplasia: Findings from the Observational PROPEL Study
Presenter: Marie-Eve Robinson, M.D., M. Sc., Shriners Hospital for Children Canada, McGill University, CA
Date & Time: Monday, June 29 at 11:00 am EDT

Skeletal Dysplasia Posters:
A Phase 2/2b Study of Infigratinib in Children Under 3 Years Old with Achondroplasia: Design of PROPEL Infant and Toddler
Presenter: Julie Hoover-Fong, M.D., Ph.D., Johns Hopkins University, U.S.
Date & Time: Sunday, June 28 at 12:00 pm EDT

The ACCEL Observational Study: Diagnostic Features, Medical History, and Baseline Characteristics of Children with Hypochondroplasia
Presenter: Marie-Eve Robinson, M.D., M. Sc., Shriners Hospital for Children Canada, McGill University, CA
Date & Time: Monday, June 29 at 12:00 pm EDT

MyAchonJourney: An Online Educational Resource for Individuals with Achondroplasia and Their Families, Developed by Advocacy Leaders and Healthcare Providers
Presenter: Kirsten Kiefer, BridgeBio Skeletal Dysplasias, U.S.
Date & Time: Monday, June 29 at 12:00 pm EDT

Qualitative Research to Evaluate the Content Validity and Relevance of Patient-Reported Outcome Measures for Children and Parents of Children with Hypochondroplasia
Presenter: Chandler Crews, The Chandler Project, U.S.
Date & Time: Monday, June 29 at 12:00 pm EDT

ADH1 Poster:
Autosomal Dominant Hypocalcemia Type 1 and Type 2: Baseline Burden of Disease and Quality of Life in Pediatric Participants in the CLARIFY Disease Monitoring Study
Presenter: Raja Padidela, M.D., Royal Manchester Children's Hospital, University of Manchester, UK
Date & Time: Monday, June 29 at 12:00 pm EDT

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn , X , Facebook , Instagram , YouTube , and TikTok .

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com


Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BridgeBio Pharma, Inc. (BBIO)

Due to inactivity, you will be
signed out in approximately: